



17 July 2017

Market Announcement Office
Australian Securities Exchange
Level 6, 20 Bridge Street
SYDNEY NSW 2000

Dear Sirs,

Investment in New Technology Start-up Pellucid Networks Pte Ltd

We are pleased to announce that the Group's wholly owned subsidiary, Zicom MedTacc Pte Ltd ("MedTacc"), an appointed Medtech Accelerator, has, jointly with SPRING Singapore, agreed to a total investment of S\$2m in a growth phase medical imaging software solutions company, Pellucid Networks Pte Ltd ("**Pellucid**").

Pellucid offers complete solutions in ophthalmic practices that use medical imaging. With their cloud based ophthalmic programs and platform, Pellucid works towards simplifying diagnosis, assessment, and treatment that would serve to address end-to-end requirements of eye screening and early detection of vision impairment.

Pellucid is revenue generating. It has successfully executed a major project awarded by the Singapore Health Ministry integrating two national eye centers with 18 Polyclinics as part of a national program to screen diabetic retinopathy. To date more than 100,000 national screenings have been completed. Regional marketing that includes ASEAN countries and Australia has been launched to exploit our success in Singapore in replicating our expertise in these countries.

Pellucid is headquartered in Singapore.

This investment has been fully funded from internal resources without external borrowings. It is part of the Group's strategy of expansion into new innovations and technologies with focus on medical technologies embracing digital health.

The Board does not expect the investment to have any immediate impact on the Group's earnings in the short term.

Yours faithfully
Zicom Group Limited

G L Sim
Chairman